What a PCAC vote does. What it does not.
A committee can recommend. The agency still has to write a rule. A vote is not a license.
PCAC is FDA’s Pharmacy Compounding Advisory Committee. It advises the agency on whether a bulk substance should be added to the 503A Bulks List — the list of ingredients a 503A compounding pharmacy may use when it compounds for an identified patient.
A yes vote is a recommendation. It does not put the substance on the list. FDA still needs notice-and-comment rulemaking: a proposed rule, public comment, a final rule. FDA is not required to follow the committee.
It is also not drug approval. Approval is a different process, for a specific product, after the sponsor files. A compounded preparation is not that product. See three kinds of peptides.
On July 23–24, 2026, PCAC recommended six peptides for the 503A Bulks List and voted against one. That meeting is the news piece. This page is the ladder: vote ≠ list ≠ license ≠ approval.
Until a final rule, the legal landscape did not change because a committee raised its hands.
Citations
- FDA briefing introduction, July 2026 PCAC
- FDA introductory remarks, July 23, 2026
- Mintz: what the vote does and does not do
Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take, how to mix it, or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.